Signs of Rheumatoid Arthritis Can Show Up Long Before Diagnosis

FRIDAY, May 10, 2019 -- Difficulties with daily activities such as dressing, walking and eating can be seen in rheumatoid arthritis patients a year or two before they're diagnosed, a new study shows. " This is a new finding, and a finding that is...
Source: - Daily MedNews - Category: General Medicine Source Type: news

Related Links:

Authors: Gearry RB, Frampton C, Inns S, Poppelwell D, Rademaker M, Suppiah R Abstract Objective: VITALITY, a 6-month, multicenter, prospective, observational study, assessed the effects of originator adalimumab (HUMIRA®) on health and disability outcomes in patients with Crohn's disease (CD), rheumatoid arthritis (RA), or psoriasis treated in routine clinical practice in New Zealand (NZ). Methods: Biologic-naïve adults initiating adalimumab in accordance with NZ funding requirements were recruited. Primary endpoint was 6-month change from baseline in World Health Organization Disability Assessment Schedule...
Source: Current Medical Research and Opinion - Category: Research Tags: Curr Med Res Opin Source Type: research
Publication date: 15 August 2019Source: International Journal of Pharmaceutics, Volume 567Author(s): Mariam Zewail, Noha Nafee, Maged W. Helmy, Nabila BoraieAbstractOral treatment of rheumatoid arthritis (RA) with the immunomodulator, leflunomide (LEF), is associated with systemic side effects namely immunosuppression and hepatotoxicity. Herein, attempts to improve LEF therapeutic outcomes via nanostructured lipid carriers (NLCs) targeting inflamed rheumatic joints were executed. LEF-NLCs coated with either chondroitin sulphate (CHS) or chitosan (CS) were around 250 nm in size with negative or positive charge, respective...
Source: International Journal of Pharmaceutics - Category: Drugs & Pharmacology Source Type: research
The phase 3, RA-BEAM study found RA patients switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections...
Source: The Rheumatologist - Category: Rheumatology Authors: Tags: Conditions Rheumatoid Arthritis adalimumab baricitinib Rheumatoid Arthritis (RA) washout Source Type: research
It is not safe to take methotrexate during pregnancy. The drug affects folic acid levels in the body and can lead to birth abnormalities. In this article, we look at the effects of taking methotrexate during conception or pregnancy, how to stay safe, and alternative medications.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Rheumatoid Arthritis Source Type: news
No abstract available
Source: Current Orthopaedic Practice - Category: Orthopaedics Tags: Case Report Source Type: research
ConclusionIn this population-based study, the use of ADT was not associated with an increased risk of RA in men with prostate cancer.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
Periodontitis is an incredibly prevalent chronic inflammatory disease, which results in the destruction of tooth supporting structures. However, in addition to causing tooth and alveolar bone loss, this oral inflammatory disease has been shown to contribute to disease states and inflammatory pathology at sites distant from the oral cavity. Epidemiological and experimental studies have linked periodontitis to the development and/or exacerbation of a plethora of other chronic diseases ranging from rheumatoid arthritis to Alzheimer’s disease. Such studies highlight how the inflammatory status of the oral cavity can have...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
Bone remodeling is strictly regulated by immune modulators to maintain the balance between bone resorption and formation. This fundamental interaction between the immune and skeletal systems termed as osteoimmunology is regulated by numerous modulators. Among these modulators the pleiotropic sphingolipid metabolite, S1P, together with its cognate receptors, the S1PRs, are known to be involved in the regulation of both immune system and bone remodeling. S1P-S1PR1 signaling is also considered an important signaling pathway capable of inducing inflammatory response that modulates both osteoclastogenesis and osteogenesis. Its ...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ConclusionsIn this real-world analysis, many patients initiating TCZ monotherapy or combination therapy were able to discontinue or decrease their prednisone dose over 12  months. Similar changes in prednisone dose were observed over 6 months.Trial identifier, NCT01402661.FundingCorrona, LLC and Genentech, Inc.Plain Language SummaryPlain language summary available for this article.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
ANAHEIM, CA - More outreach is needed to explain the value of nuclear medicine...Read more on AuntMinnie.comRelated Reading: SNMMI: PET ligand can diagnose brain disorder before autopsy SNMMI: PET ligand can diagnose brain disorder before autopsy SNMMI: Technetium radiotracer tracks rheumatoid arthritis SNMMI: FDG-PET/MRI improves pain diagnosis, management Video from SNMMI 2019: Dr. Barry Siegel on PET reimbursement
Source: Headlines - Category: Radiology Source Type: news
More News: Arthritis | General Medicine | Rheumatoid Arthritis | Rheumatology | Study